AbbVie beats estimates but stock dips

AbbVie (NYSE:ABBV) reported Q3 earnings of $3.82 per share, beating estimates by $0.08, with revenue of $17.4B, up 10.3% YoY. The company raised its 2026 EPS guidance to $13.95-$13.99, in line with consensus. Shares fell 3% premarket. Key drugs like Skyrizi and Rinvoq drove growth, while Humira sales declined 31.2%. AbbVie also increased its quarterly dividend by 5.2%.

Original reporting
Published Oct 30, 2026, 11:55 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 12:12 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ABBV
Bearish
high confidence
Mentioned
$ABBV
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ABBVBearishHigh
01

Why it matters

Earnings beat and guidance raise are modest; market reaction is a 3% pre‑market decline, indicating investors may be pricing in concerns over Humira decline and R&D expenses.

02

Market read

First‑report earnings data for a large‑cap pharma company with immediate price impact.

03

What to watch

The 5.2% dividend increase and acquisition of Apogee Therapeutics could support longer‑term upside.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

AbbVie posted Q3 adjusted EPS of $3.82 vs $3.74 estimate and revenue of $17.4B vs $17.36B estimate, raising FY2026 EPS guidance to $13.95‑$13.99.

Company-level read

Ticker impact

$ABBVBearishHigh confidence
Context

AbbVie reported Q3 earnings beat and raised FY2026 EPS guidance, but shares fell 3% pre‑market.

Expected impact

likely pressure as the market prices in the guidance that is only marginally above consensus and the stock already slipped 3% pre‑market.

Evidence & confidence

First‑report earnings data with concrete numbers for EPS, revenue, and guidance; large‑cap impact; immediate price reaction.

Market effects

Pharma sector may see modest pullback as AbbVie's guidance aligns with consensus, limiting upside for peers.

U.S. large‑cap healthcare index could face slight downside pressure.

Limited; primarily U.S. market impact.

Counterpoint

Guidance is in line with expectations; the dip may be an overreaction, presenting a buying opportunity.

Key entities

  • AbbVie Inc.

    Pharmaceutical company reporting Q3 results.

Related articles

$ABBVMed

AbbVie to Invest More than $200 Million in Puerto Rico to Modernize Barceloneta Manufacturing Campus

AbbVie (NYSE: ABBV) plans to invest $217 million to modernize its biologics manufacturing campus in Puerto Rico, creating 100 new jobs. The project, part of a $100 billion U.S. investment commitment, will integrate AI and advanced technologies to support current and future immunology and neuroscience medications. The facility is expected to be operational by 2030.

$ABBVHighAI 9/10

AbbVie expands bispecific cancer med push with up to $2.5 billion deal with Germany's Disco

AbbVie will pay up to $2.54 billion to develop cancer treatments with private German biotech Disco Pharmaceuticals, including a $40 million upfront fee and milestone payments. Disco will handle research, with AbbVie having exclusive licensing rights. The deal focuses on AND-gated bispecific therapeutics for solid tumors, with Disco aiming to select a candidate in late 2024.